Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Swen

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
BMC Medicine|June 15, 2019
Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The NetherlandsP C D Bank, J J Swen, H J Guchelaar
Journal of Gastrointestinal Cancer|December 28, 2016
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-FluorouracilCatc Lunenburg, J J Swen, H-J Guchelaar, et al.
Annual Review of Pharmacology and Toxicology|September 30, 2024
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical ImplementationR Mosch, M van der Lee, H J Guchelaar, et al.
Clinical Pharmacokinetics|May 31, 2013
The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugsN van Leeuwen, J J Swen, H-J Guchelaar, et al.
Clinical Pharmacology and Therapeutics|January 23, 2014
Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencingH-J Guchelaar, H Gelderblom, T van der Straaten, et al.
Drug Discovery Today|April 22, 2014
Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokineticsM H ten Brink, J Zwaveling, J J Swen, et al.
Clinical Pharmacology and Therapeutics|May 28, 2013
Pharmacogenetics in transplant patients: mind the mixM H Ten Brink, T van der Straaten, H Bouwsma, et al.
European Journal of Clinical Pharmacology|August 30, 2017
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolismA B Sanchez Spitman, D J A R Moes, H Gelderblom, et al.
Scientific Reports|January 12, 2021
Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapseA B Sanchez-Spitman, J J Swen, V O Dezentjé, et al.
Clinical Pharmacology and Therapeutics|August 31, 2013
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingK E Caudle, C F Thorn, T E Klein, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
BMC Medicine|June 15, 2019
Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The NetherlandsP C D Bank, J J Swen, H J Guchelaar
Journal of Gastrointestinal Cancer|December 28, 2016
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-FluorouracilCatc Lunenburg, J J Swen, H-J Guchelaar, et al.
Annual Review of Pharmacology and Toxicology|September 30, 2024
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical ImplementationR Mosch, M van der Lee, H J Guchelaar, et al.
Clinical Pharmacokinetics|May 31, 2013
The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugsN van Leeuwen, J J Swen, H-J Guchelaar, et al.
Clinical Pharmacology and Therapeutics|January 23, 2014
Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencingH-J Guchelaar, H Gelderblom, T van der Straaten, et al.
Drug Discovery Today|April 22, 2014
Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokineticsM H ten Brink, J Zwaveling, J J Swen, et al.
Clinical Pharmacology and Therapeutics|May 28, 2013
Pharmacogenetics in transplant patients: mind the mixM H Ten Brink, T van der Straaten, H Bouwsma, et al.
European Journal of Clinical Pharmacology|August 30, 2017
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolismA B Sanchez Spitman, D J A R Moes, H Gelderblom, et al.
Scientific Reports|January 12, 2021
Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapseA B Sanchez-Spitman, J J Swen, V O Dezentjé, et al.
Clinical Pharmacology and Therapeutics|August 31, 2013
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingK E Caudle, C F Thorn, T E Klein, et al.
Pageof 4